<DOC>
	<DOC>NCT02131051</DOC>
	<brief_summary>This is a comparative, open label, parallel group, non interventional study to further demonstrate the effectiveness and tolerability of Ectoin Allergy Nasal Spray and Eye drops. In addition the effectiveness and safety shall be compared to Azelastine containing nasal Sprays and Eye drops. The patient applied EctoinÂ® Rhinitis Nasal Spray / Eye drops or takes Azelastine nasals spray and eye drops according to the instructions for use. The observation takes place over a period of 7 days. Response to treatment is recorded at day 7 by the physician and in daily by the patient in a dairy.</brief_summary>
	<brief_title>Application of Ectoine Containing Nasal Spray and Eye Drops in Patients With Allergic Rhinitis</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis, Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Conjunctivitis, Allergic</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<mesh_term>Azelastine</mesh_term>
	<criteria>male or female patients aged 1870 years Patients with proven allergy and acute symptoms in nose and eye which are treated with Ectoin Allergy Nasal Spray and Ectoin Allergy Eye Drops or Azelastine Nasal Spray and Azelastine Eye Drops during the observational period pregnancy and nursing women, drug addicts and persons unable to give consent to study participation, patients with intolerance against ingredients of any of the study treatments, previous eye or nose surgery, concomitant treatment with antiallergic drugs, and diseases which might influence the output of the study according to the physicians' judgment. contra indications according to the label</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>ectoine</keyword>
	<keyword>allergic rhinitis</keyword>
	<keyword>bitop</keyword>
</DOC>